-1753361094794.webp&w=3840&q=75)
2025 NOSCM | Updates on ROS-1, RET, BRAF, MET & NTRK
0% Complete
Course Overview
Dr. Janakiram Subramanian discussed KRAS and HER2 mutations, noting the potential of new agents like zongertinib.
Course Content
Credits
- AMA PRA Category 1 Credit™Non-CME
Course Details
- Duration
- 0.00 hour
- Released
- Jul 25, 2025
- Last Review
- Jul 25, 2025
- Expires
- Jul 25, 2026
Target Audience
Physicians
Nurses
Pharmacists
Physician Associates
Faculty & Disclosure
Faculty
Janakiram Subramanian, MD, MPH
Accreditation
NA
